Franciscus M. H. de Groot

Author

Also Known As

F. M. H. DE GROOT, Franciscus Groot, Franciscus M H de Groot, Franciscus M. H. De Groot, Franciscus M. H. de Groot, Franciscus M.H de Groot, Franciscus M.H. de Groot

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Synthon (Netherlands)

About

Franciscus M. H. de Groot is an author at Radboud University Nijmegen specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	745
2	Natural Sciences	6	6	553
3	Biochemistry	4	4	303
4	Biomolecular Engineering	2	2	301
5	Biomedical Engineering	1	1	117

Franciscus M. H. de Groot

Publications

Citations

H-Index

Page 1

	Year	Citations
“Cascade‐Release Dendrimers” Liberate All End Groups upon a Single Triggering Event in the Dendritic Core Franciscus M. H. de Groot, C. Albrecht, Ralph Koekkoek, Angewandte Chemie International Edition	2003	237
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985 Ronald C. Elgersma, Ruud G. E. Coumans, Tijl Huijbregts, Molecular Pharmaceutics Molecular BiologyDuocarmycin 3BPharmaceutical ChemistryMedicinal ChemistryToward Selection	2015	214
Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release Franciscus M. H. de Groot, Walter J. Loos, Ralph Koekkoek, The Journal of Organic Chemistry Combinatorial ChemistryNovel Spacer SystemsCyclization Spacer SystemsBiomedical EngineeringPharmaceutical Chemistry	2001	117
Synthesis and Biological Evaluation of 2‘-Carbamate-Linked and 2‘-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin Franciscus M. H. de Groot, Leon W. A. van Berkom, Hans W. Scheeren Journal of Medicinal Chemistry PharmacotherapySelective ActivationPharmaceutical ChemistryTumor BiologyMedicinal Chemistry	2000	103
Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Franciscus M. H. de Groot, Henk J. Broxterman, Hans P. H. M. Adams, PubMed Tumor BiologyMedicinal ChemistryTumor-associated Protease PlasminDrug TargetingMedicine	2002	87
Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin Franciscus M. H. de Groot, A.C.W. de Bart, Jan H. Verheijen, Journal of Medicinal Chemistry	1999	66
Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue Eric W. P. Damen, Tapio Nevalainen, Toine J. M. van den Bergh, Bioorganic & Medicinal Chemistry Bioreductive ActivationMedicineHypoxic Tumour TissueTumor TargetingAnti-cancer Agent	2002	62
Novel 20-Carbonate Linked Prodrugs of Camptothecin and 9-Aminocamptothecin Designed for Activation by Tumour-Associated Plasmin Franciscus M. H. de Groot, Guuske F. Busscher, R. W. M. ABEN, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryNatural SciencesMedicineTumour-associated Plasmin	2002	48
Plasmin‐activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity Laetitia Devy, Franciscus M. H. de Groot, Silvia Blacher, The FASEB Journal Chemoprevention StrategyImmunologyPharmacotherapyElongated SpacerSystemic Toxicity	2004	43
“Cascade‐Release Dendrimers” Liberate All End Groups upon a Single Triggering Event in the Dendritic Core Franciscus M. H. de Groot, Carsten Albrecht, Ralph Koekkoek, Angewandte Chemie Dendritic BiologySingle Triggering EventSystems BiologySignal TransductionDendritic Processing	2003	36

Page 1